Table 2. Analysis of potential prognostic factors for overall survival.
| Characteristic | Median OS (months) | Univariate analysis | Multivariate analysis | |||||
|---|---|---|---|---|---|---|---|---|
| HR | 95% CI | P | HR | 95% CI | P | |||
| Sex (male vs. female) | 15.3 vs. 16.4 | 0.95 | 0.75–1.19 | 0.657 | 1.08 | 0.85–1.37 | 0.518 | |
| Age (≤60 vs. >60 years) | 14.7 vs. 16.4 | 0.81 | 0.66–1.00 | 0.054 | 0.85 | 0.68–1.06 | 0.151 | |
| ECOG PS (0 vs. 1) | 13.5 vs. 16.1 | 0.92 | 0.71–1.20 | 0.553 | 0.96 | 0.73–1.26 | 0.774 | |
| Tumor site (cervical/upper thoracic vs. middle/lower thoracic) | 17.1 vs. 16.2 | 1.02 | 0.89–1.16 | 0.773 | 1.02 | 0.89–1.17 | 0.789 | |
| Tumor length (≤5 vs. >5 cm) | 16.3 vs. 15.7 | 0.95 | 0.76–1.18 | 0.631 | 0.93 | 0.74–1.15 | 0.484 | |
| Metastasis (one site vs. >one site metastasis) | 16.8 vs. 14.7 | 1.25 | 1.02–1.54 | 0.035 | 1.06 | 0.86–1.31 | 0.592 | |
| Treatment regimen (CCRT vs. CT alone) | 16.8 vs. 14.8 | 1.23 | 1.01–1.52 | 0.056 | 1.20 | 0.97–1.49 | 0.096 | |
| Response (CR/PR vs. SD/PD) | 19.3 vs. 11.2 | 2.29 | 2.06–2.76 | <0.001 | 2.37 | 2.04–2.75 | 0.000 | |
HR, hazard ratio; CI, confidence index; ECOG, Eastern Cooperative Oncology Group; PS, Performance Status; CCRT, concurrent chemoradiotherapy; CT, chemotherapy; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.